Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

When done right, pairing quality and value can be an especially potent investing strategy. Medtronic's revenue edged higher as currency-neutral non-GAAP EPS dipped a bit in the fiscal fourth quarter. Relative to its size, the company's $17 billion in net debt is quite manageable.

Medtronic: Now Is The Time To Buy This Deep Value Dividend Aristocrat

Novo Nordisk

Novo Nordisk and Medtronic are longtime leaders in the healthcare industry. Both are proven innovators with attractive prospects in the years ahead.

Got $200? 2 Healthcare Stocks to Buy and Hold Forever.

MDT stock enjoys a bullish rating from analysts and Seeking Alpha writers. But insider transactions are completely dominated by selling - for good reasons in my view. The valuation is not as attractive as on the surface once growth is factored in.

Medtronic: Why I Disagree With The Crowd

Medtronic plc (NYSE:MDT ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:40 AM ET Company Participants Geoff Martha - Chairman & Chief Executive Officer Conference Call Participants David Roman - Goldman Sachs David Roman Good morning, everybody. I want to welcome everyone here to the 45th Annual Global Healthcare Conference.

Medtronic plc (MDT) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.

Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes

DUBLIN , June 6, 2024  /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 45th annual Goldman Sachs global healthcare conference on Tuesday, June 11, 2024. Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the company beginning at 10:40 a.m.

Medtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference

Medtronic has been increasing its dividend for decades. But the rate of its increases has slowed drastically in recent years.

Medtronic Raised Its Dividend for a 47th Straight Year, But Here's Why It Isn't a Great Dividend Growth Stock

Medtronic's (NYSE: MDT) diabetes segment, which sells insulin pumps, continuous glucose monitoring systems, and consumables has seen its revenue rise at a slower pace of 1.4% annually from $2.4 billion in fiscal 2020 (fiscal ends in April) to $2.5 billion in fiscal 2024. The slower growth can be attributed to unfavorable currency translation, given that over 60% of the segment sales are derived from markets outside the U.S. However, we think the company will see a pickup in diabetes sales going forward.

With Less Than 10% Contribution To Sales How Important Is The Diabetes Segment For Medtronic Stock?

Abbott Labs

Deere & Company

Diamondback Energy

Old Dominion Freight Line

Recent data indicates a heightened risk of stagflation, with slowing economic growth and persistent inflation. This poses challenges for the economy and portfolios, but also presents opportunities to buy beaten-down stocks with strong pricing power and growth potential. My focus remains on resilient dividend growth stocks and sectors like energy and healthcare, which are well-positioned for these conditions.

The 2 Most Important Charts I Want (Dividend) Investors To See

Prologis

AT&T

Dividend stocks are the best way to play a market potentially on the cusp of a massive rebound, thanks to the Federal Reserve potentially cutting rates three times if inflation stays low, which has made the market more optimistic. The latest Bureau of Economic Analysis report shows that inflation cooled slightly in April.

Dividend Delights: 3 Stocks That Will Sweeten Your Investment Returns

Acuity Brands

Atlanta Braves Holdings Inc

Gigacloud Tech

Jazz Pharmaceuticals

Titan Machinery

Vici Properties

Finding overlooked stocks (worth investing in) is tough in today's market. While you can screen for micro-caps, pink sheet stocks, and similar speculative investments, most of the best blue-chip and long-term stocks are well-known and heavily invested in.

7 Overlooked Stocks Offering Long-Term Stability From the Shadows

DUBLIN , June 3, 2024 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €850,000,000 principal amount of 3.650% senior notes due 2029, €850,000,000 principal amount of 3.875% senior notes due 2036, €600,000,000 principal amount of 4.150% senior notes due 2043, and €700,000,000 principal amount of 4.150% senior notes due 2053 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A.

Medtronic announces closing of public offering of €3.0 billion of senior notes

Chevron

Dollar Tree

The summer doldrums are almost upon us. June is absolutely the worst month in which to invest, no matter the market index.

Beat the Heat: 3 Stocks to Buy Before the Summer Slowdown Sets In

AXA Equitable Holdings Inc

Hamilton Lane

Ralph Lauren

SpartanNash

Investors may keep a tab on stocks like HLNE, RL, SPTN, EQH and MDT, which have lately hiked their dividend payments.

Watch These 5 Stocks That Recently Hiked Dividends

Medtronic exceeded quarterly forecasts last week, but its stock got punished anyway. Shares cost nearly 30x earnings, but those earnings are growing painfully slowly.

Medtronic Stock Is a Sell, According to 1 Wall Street Analyst

DUBLIN , May 29, 2024 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the "Offering") of €850,000,000 principal amount of 3.650% senior notes due 2029, €850,000,000 principal amount of 3.875% senior notes due 2036, €600,000,000 principal amount of 4.150% senior notes due 2043, and €700,000,000 principal amount of 4.150% senior notes due 2053 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A.

Medtronic announces pricing of €3.0 billion of senior notes

DexCom

Stryker

In a recent deep-dive research report on the state of the MedTech (medical technology) sector, Oppenheimer highlighted the potential of artificial intelligence (AI) in the sector, noting its capacity to save an estimated $200 billion to $300 billion annually through enhanced workflow management. Inspired by these findings, this article explores the three best MedTech stocks to buy now, each poised to capitalize on AI-driven advancements.

The 3 Best MedTech Stocks to Buy Now: May 2024

Becton, Dickinson and Co.

Franklin Resources

C.H. Robinson Worldwide

Clorox

Ecolab

Federal Realty Investment Trust

Hormel Foods

McCormick

Realty Income Corp

J. M. Smucker

Stanley Black & Decker

Target

The ProShares S&P 500 Dividend Aristocrats ETF hits its first speed bump in April, dropping by 4.69%. Some of this loss has been recovered in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 34 months of tracking these strategies, one strategy is outperforming NOBL, while 2 remain relatively close.

My Best Dividend Aristocrats For June 2024

H&R Block

Dividend stocks are making a comeback in portfolios after a period where higher interest rates made fixed-income options more attractive to income investors. As these investors return to dividend stocks, the criteria for selecting the best options have evolved — a trend that applies to most stock segments today.

If You Can Only Buy One Dividend Stock in May, It Better Be One of These 3 Names

Comcast

Dow Inc

Duke Energy

Johnson & Johnson

Kinder Morgan

Altria

PNC Financial Services

SPDR S&P 500 ETF Trust

Sempra Energy

Verizon

Morningstar published their 10 Best Dividend Stocks, which are undervalued blue-chip stocks with reliable dividends. The article analyzes the valuation and estimated future total return of each stock, comparing them to the S&P 500. Comcast has the highest potential rate of return among the 10 stocks, while Sempra has the lowest.

Going Beyond Morningstar's 10 Best Dividend Stocks List

Home Depot

Kroger

Earlier, the Federal Reserve stood poised to cut the benchmark interest rate, which boded well for reliable dividend stocks. Essentially, Uncle Sam's high yields wouldn't compete with the passive income stemming from private enterprises.

Reliable Rewards: 7 Dividend Stocks to Count On in Any Market

Medtronic's fair price estimate is $142.20, indicating a 73.3% upside from $82.07, with potential annual returns of 28.8% through 2029. FQ4 2024 earnings exceeded expectations with an EPS of $1.46 and revenue of $8.59 billion. Medtronic focuses on innovation through AI, data analytics, and new partnerships, enhancing competitiveness and product offerings.

Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued

Medtronic stock reacted negatively to an earnings report that many Wall Street analysts found encouraging. Wells Fargo raised its price target for Medtronic to $105 per share.

Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?

News for Medtronic Stock (MDT)